Healthcare data exchange firm Rymedi has raised $9m in a Series A funding round to increase security and accessibility for patients. The financing came from RW3 Ventures, White Star Capital, Blockchange Ventures, Avalanche’s Blizzard Fund, and various angel investors. Rymedi offers a blockchain-based system to customers and patients that improves data transfer and entry, and maintains regulatory standards.
StockWatch: New UC Data Sparks Smoother Sailing for Abivax
Less than a month after its stock roller-coastered on safety signals associated with its late-stage ulcerative colitis (UC) drug candidate obefazimod, shares of Abivax (Euronext
